Use of Anticoagulants in COVID-19: A Review

Conclusions: Substantial high-quality data support practice changes to COVID-19 thromboprophylaxis. Risk stratification by setting, disease severity, and biomarkers such as D-dimer is critical in considering choice, dose, and duration of anticoagulants.
Source: American Journal of Therapeutics - Category: Drugs & Pharmacology Tags: Therapeutic Advance Source Type: research